Axilea LLC

Axilea LLC, which operates as ImmunoMetabolix, is a clinical-stage biotechnology company that utilizes a proprietary engineering approach to develop metabolically-fit immunotherapies. The company focuses on addressing cancer, autoimmune, and inflammatory diseases where existing treatments may be ineffective, costly, or cause significant side effects. By targeting metabolic dysfunctions that can impair the immune system, their core technology, the iMET platform, is designed to generate more potent T-cells capable of specifically killing cancer cells or inhibiting inflammatory processes.

The company's work aims to provide enhanced therapeutic efficacy and patient safety for those suffering from complex immune-related disorders. Originally spun out of research at Arizona State University, the organization works to translate advancements in cell metabolism into actionable healthcare solutions. By focusing on the metabolic fitness of immune cells, the company seeks to offer patients improved outcomes and better quality of life through novel, patient-centric clinical interventions.